

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Joakim Nordanstig

Page 1/3

Wednesday, January 27, 2021

MAIN ARENA 1

- 13:55 – 15:10** **SYMPOSIUM: Spotlight on challenging lower limb cases: tips and tricks for success**
supported by BD
MODERATOR:
Dierk Scheinert
PANEL:
Bruno Freitas
Luis Palena
Marc Sirvent
- 13:55 – 14:03 No increase in all-cause mortality with paclitaxel devices used in lower limb arterial interventions - an interim analysis of SWEDEPAD RCT data
Joakim Nordanstig
- 14:03 – 14:18 Recorded case presentation: the importance of vessel prep before DCB to fight against CLI recurrence
Luis Palena
- 14:18 – 14:33 Recorded case: Chronic in-stent re-occlusion left SFA
Andrej Schmidt
- 14:33 – 14:53 Recorded case: Rotarex™S: Rotational atherothrombectomy catheter for an extreme rescue of a previous iliofempop, endovascular treatment for CTLI
Marc Sirvent
- 14:53 – 15:10 Q&A, discussion, and conclusion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

The logo for the Leipzig Interventional Course (LINC) features the letters 'L I N C' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element curves behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Joakim Nordanstig

Page 2/3

Wednesday, January 27, 2021

MAIN ARENA 1

- 19:00 – 20:20** **VIVA/LINC – Joint session on the current status and future of drug-eluting therapies**
MODERATOR:
Dierk Scheinert
Peter Schneider
PANEL:
Andrew Holden
Marianne Brodmann
Robert Lookstein
- 19:00 – 19:03 Introduction by the moderators
Dierk Scheinert
Peter Schneider
- 19:03 – 19:08 Insights on paclitaxel safety from the femoral-popliteal RCTs
Peter Schneider
- 19:08 – 19:13 Insights on paclitaxel safety from femoral-popliteal real-world data
Eric Secemsky
- 19:13 – 19:21 New insights from the interim safety analysis of the SWEDEPAD study
Joakim Nordanstig
- 19:21 – 19:26 How does the Voyager data help us understand the risks of paclitaxel?
Marc Bonaca
- 19:26 – 19:31 Paclitaxel safety in patients with CLTI
Marianne Brodmann
- 19:31 – 19:36 Newly FDA-approved paclitaxel devices for lower extremity and dialysis and the regulatory implications
Robert Lookstein
- 19:36 – 19:41 New data on paclitaxel in the next couple of years; what should we expect?
Eva Freisinger
- 19:41 – 19:49 Panel discussion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Joakim Nordanstig

Page 3/3

Wednesday, January 27, 2021

- | | |
|---------------|---|
| 19:49 – 19:54 | Paclitaxel vs. limus agents. Mechanism of action, what are the challenges to move beyond paclitaxel?
Sahil Parikh |
| 19:54 – 19:59 | Previous experience with limus compounds in the non-coronary arteries; lessons learned
Thomas Zeller |
| 19:59 – 20:04 | New limus delivering devices for above and below knee occlusive disease; when to expect results?
Andrew Holden |
| 20:04 – 20:14 | Blue horizon keynote speech: Potential for drug delivery in the treatment of lower extremity occlusive disease: what will the practice look like in 5 years?
Dierk Scheinert |
| 20:14 – 20:20 | Panel discussion |

We are asking all faculty members to strictly respect the given time limits.